📰 Allogeneic News
Page 7 - Allogeneic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.
March 3, 2022
- Mocravimod is being developed as a potential best-in-class adjunctive and maintenance therapy to enhance the curative potential of HSCT for AML patients - A global registration-enabling
December 11, 2021
Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or...
December 6, 2021
SOUTH SAN FRANCISCO - Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer... | December 6, 2021
November 30, 2021
The EMA has validated Atara Biotherapeutics' Marketing Authorization Application (MAA) for tabelecleucel (tab-cel), the first time an off-the-shelf allogeneic T-cell therapy will be evaluated by any regulatory agency in the world.
November 4, 2021
Two abstracts will be presented in a pre-recorded poster presentation and oral session Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD)
November 3, 2021
Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomasSINGAPORE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics
October 27, 2021
Acquisition expands Takeda's immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging gamma-delta T cells for the potential treatment of solid tumors and hematological
August 7, 2021
De legendarische tv-serie ‘Allo ‘Allo! krijgt in het Verenigd Koninkrijk voortaan een waarschuwing mee wanneer het uitgezonden of in een streamingkanaal aa...
May 20, 2021
First-in-human clinical study for Acute Myeloid Leukaemia expected to begin later in 2021 FDA also granted orphan drug designation to GDX012 for the treatment of Acute Myeloid Leukaemia GammaDelta
May 14, 2021
(0) Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021 BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24 th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021). The presentation at ASGCT 2021 will highlight data from six patients tre...